Sorry, you need to enable JavaScript to visit this website.
Skip to main content

This site is intended for US Population-Health Decision Makers or similar entities at hospitals and US oncology practices.

Select Components of an MPN Quality Initiative

Oncology practices across the country are recognizing the importance of developing and continually improving quality care.1,2 Quality Initiatives are an essential component for maintaining accreditation from organizations such as URAC®, ACHC, ASCO, and The Joint Commission.

Patients with MPNs are a population that may benefit from disease-specific quality programs. MPN Quality Initiatives are focused on the goal of helping to improve patient care. A successful Quality Initiative begins with proper planning through gathering the data about your target patient population and partnering with the other members of the practice team for implementation. Tracking the progress of the quality initiative can demonstrate areas for improvement, as well as identify success stories to share.

*Prior to 1996, URAC® was known as Utilization Review Accreditation Commission.

Blood Drop Icon


Monitoring lab values and blood counts

Pill Bottle Icon


Optimizing dosing

Spleen Icon


Assessing the spleen

Clipboard Icon


Tracking symptoms (MPN-SAF TSS)

Improved patient experience

*Prior to 1996, URAC® was known as Utilization Review Accreditation Commission.

Why Quality Care Matters

Quality Initiatives encourage a culture of excellence and self-examination that helps deliver quality care3

Quality care benefits patients

Organizations with Medically Integrated Dispensing Pharmacies (MIDPs) provide multidisciplinary care, with (pharmacy) providers remaining close to patients throughout their care journey4

Practices can pursue MIDP-focused Oncology Practice Certification

There is a growing trend of programs designed to evaluate an oncology practice’s performance against quality measures and standards established by oncology experts5

New incentives from CMS create opportunities

Oncology Care Model (OCM) [evolving to Enhancing Oncology Model (EOM) in July 2023], and Value-Based Contract (VBC) agreements, which are performance-based, create the need to broadly monitor the quality of care cancer patients receive6-8

Why Patients With Myeloproliferative Neoplasms Need QIs

MPNs are rare hematopoietic stem cell disorders9,10

  • MPNs are characterized by clonal expansion and transformation into aggressive forms of bone marrow failure or acute leukemias9,11

Each type of MPN can evolve into another type, making diagnosis, risk assessment, and therapeutic strategies difficult9-11

  • Patients with rare cancers—including MPNs—face therapeutic challenges, including incorrect/late diagnosis and lack of definite treatment protocols and guidelines10

How QIs can help patients with MPNs

  • Patients with MPNs could benefit from the close monitoring and specialized care that Quality Initiatives may help deliver
  • Multidisciplinary engagement in the practice, together with the commitment of a Quality Initiative champion, are keys to successful implementation

References: 1. Hewitt M, Simone JV. Ensuring Quality Cancer Care. Washington, DC: National Academy Press, 1999. 2. Neuss MN, Desch CE, et al. A process for measuring the quality of cancer care: the Quality Oncology Practice Initiative. J Clin Oncol. 2005;23(25):6233-6239. 3. Quality initiatives in action: real world impact on patients with polycythemia vera. © 2021, Incyte Corporation. 4. Barbor M. Eighth Annual Guide to Patient Support Services. 2022 Desk Reference. 5. QOPI certified practices. Association for Clinical Oncology. Accessed March 9, 2023. 6. Oncology Care Model. Updated July 2022. Accessed October 18, 2022. 7. Enhancing Oncology Model. Accessed October 18, 2022. 8. Bailey PV. The why, what, where, and how of value-based contracts. Bulletin of the American College of Surgeons. June 3, 2021. Accessed March 9, 2023. 9. Spivak JL. Myeloproliferative neoplasms. New Engl J Med. 2017;376(22):2168-2181. 10. Pillai RK, Jayasree K. Rare cancers: challenges & issues. Indian J Med Res. 2017;145(1):17-27. 11. Tefferi A, Pardanani A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncol. 2015;1(1):97-105.